DOCSLIB.ORG

Annual Report 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2016 Annual report 2016 ROCE EBITA margin CFFO Order intake (DKKm) (DKKm) 8.5% 7.1% 1,447 18,303 Down from 10.3% Down from 8.0% Up from DKK 538 Down from DKK 18,490 CONTENTS MANAGEMENT’S REVIEW 3-69 Group Financial Highlights (5-year summary) 3 Main conclusions 4-6 FLSmidth at a glance 7-9 Meet the Chairman and the Group CEO 10 Strategy and Business model 11-19 10 Financial performance 20-33 MEET THE CHAIRMAN AND CEO Divisional performance 34-41 Understand what is at the top of Key Innovations 42-47 management’s agenda. Risk Management 48-50 Sustainability performance 51 Corporate governance at a glance 52 Board of Directors 53-55 Group Executive Management 56-57 Shareholder information 58-60 Company Announcements 2016 61 Statement by management on the annual report 62 4-6 Independent auditor’s report 63-67 Quarterly key figures 68-69 MAIN CONCLUSIONS Quickly comprehend the takeaways from the Annual Report. CONSOLIDATED FINANCIAL STATEMENTS 70-137 Contents and list of notes 71 Consolidated income statement 72 Consolidated statement of comprehensive income 73 Consolidated cash flow statement 74 Consolidated balance sheet 75 Consolidated equity 77 Notes to the consolidated financial statements 79 66-67 List of group companies 133-134 QUARTERLY KEY FIGURES PARENT COMPANY FINANCIAL STATEMENTS 138-147 Check the past two year’s quarterly Parent company income statement 139 developments. Parent company balance sheet 140 Parent company equity 141 Notes to the parent company financial statements 142-147 68 FINANCIAL STATEMENTS Dive into the numbers and the explanatory notes. FLSMIDTH ANNUAL REPORT 2016 / 2 GROUP FINANCIAL HIGHLIGHTS (5-YEAR SUMMARY) / BACK TO CONTENTS GROUP FINANCIAL HIGHLIGHTS 5-YEAR SUMMARY DKKm 2012 2) 2013 2) 2014 2) 2015 2016 2016 EUR 1) INCOME STATEMENT Revenue 24,283 25,027 20,499 19,682 18,192 2,443 Gross profit 6,193 5,060 5,125 4,946 4,581 615 EBITDA 2,959 1,618 2,106 1,878 1,588 213 EBITA 2,703 1,379 1,823 1,582 1,289 173 EBIT 2,189 67 1,416 1,141 881 118 Earnings from financial items, net (61) (227) (137) (256) (54) (7) EBT 2,128 (160) 1,279 885 827 111 Profit/(loss) for the year, continuing activities 1,415 (472) 881 603 590 79 Profit/(loss) for the year, discontinued activities (112) (312) (68) (178) (68) (9) Profit/(loss) for the year 1,303 (784) 813 425 522 70 CASH FLOW CFFO 1,720 (157) 1,298 538 1,447 195 Acquisition of tangible assets (739) (524) (366) (139) (203) (27) CFFI (3,398) (567) (598) 750 (194) (26) Free cash flow (1,678) (724) 700 1,288 1,253 169 Free cash flow adjusted for acquisitions and disposals of enterprises and activities 830 (751) 884 415 1,253 169 Net working capital 1,553 2,027 2,276 2,583 2,099 282 Net interest-bearing debt (3,189) (4,780) (4,593) (3,674) (2,525) (340) ORDERS Order intake, continuing activities 27,702 19,794 17,267 18,490 18,303 2,462 Order backlog, continuing activities 29,343 20,813 17,726 14,858 13,887 1,868 BALANCE SHEET Total assets 31,875 27,328 26,352 24,362 24,112 3,243 Equity 9,419 6,922 7,761 7,982 8,462 1,138 Proposed dividend to shareholders 479 106 461 205 307 41 FINANCIAL RATIOS Gross margin 25.5% 20.2% 25.0% 25.1% 25.2% 25.2% EBITDA margin 12.2% 6.5% 10.3% 9.5% 8.7% 8.7% EBITA margin 11.1% 5.5% 8.9% 8.0% 7.1% 7.1% EBIT margin 9.0% 0.3% 6.9% 5.8% 4.8% 4.8% EBT margin 8.8% -0.6% 6.2% 4.5% 4.5% 4.5% CFFO / Revenue 7.1% -0.6% 6.3% 2.7% 8.0% 8.0% Cash conversion 37.9% n/a 62.4% 36.4% 142.2% 142.2% Book-to-bill (order intake/revenue) 114.1% 79.1% 84.2% 93.9% 100.6% 100.6% Order backlog / Revenue 120.8% 83.2% 86.5% 75.5% 76.3% 76.3% Return on equity 14% -10% 11% 5% 6% 6% Equity ratio 30% 25% 29% 33% 35% 35% ROCE (return on capital employed), average 17.9% 9.2% 12.1% 10.3% 8.5% 8.5% Net working capital ratio, average 8.3% 7.1% 10.5% 12.3% 12.9% 12.9% Financial gearing 1.2 3.0 2.2 2.0 1.6 1.6 Capital employed, average 13,205 15,070 15,040 15,162 15,157 2,039 Number of employees at 31 December, Group 15,900 15,317 14,765 12,969 12,187 12,187 SHARE RATIOS CFPS (cash flow per share), (diluted) 33.0 (3.1) 26.3 11.0 29.5 3.8 Free cash flow yield 4.8% n/a 6.3% 3.4% 8.3% 8.3% EPS (earnings per share), (diluted) 25.1 (15.3) 16.4 8.6 10.6 1.4 BVPS (Book value per share) 181 139 158 162 172 23 Dividend per share 9 2 9 4 6 0.8 Pay-out ratio 37% n/a 57% 49% 59% 59% FLSmidth & Co. A/S´ share price 327.2 296.1 272.3 240.0 293.0 39.4 Number of shares (1,000), 31 December 53,200 53,200 51,250 51,250 51,250 51,250 Market capitalisation 17,407 15,753 13,955 12,300 15,016 2,020 The financial ratios have been computed in accordance with the guidelines of the Danish Society of Financial Analysts from 2015. Please refer to note 7.15 for definitions of terms in the consolidated financial statements. 1) Income statement and cash flow items are translated at the average EUR exchange rate of 7.4454 and the balance sheet items are translated at the year-end EUR exchange rate of 7.4344. 2) The income statement figures have been restated as Cembrit and bulk material handling activities are presented as discontinued activities. FLSMIDTH ANNUAL REPORT 2016 / 3 MAIN CONCLUSIONS / BACK TO CONTENTS FINANCIAL RESULTS 2016 KEY PERFORMANCE INDICATORS 2016 (part of management’s short- and long-term incentive Following a slow start to the year, market programmes) activity resumed in the second half. Capital 2016 2015 orders remained subdued throughout 2016, whereas service orders showed good Financial momentum in the second half. Improved Order intake DKK 18,303m DKK 18,490m working capital and strong operating cash ROCE 8.5% 10.3% flow led to a significant debt reduction. Net Working Capital% (end) 11.5% 13.1% Revenue was above and the EBITA EBITA margin 7.1% 8.0% margin was within 2016 guidance. Non-financial A similar level of revenue and EBITA Safety (LTIFR)1) 1.5 1.8 margin is expected in 2017. Quality (DIFOT)2) 84% 77% 1) LTIFR = Lost time injury frequency rate 2) DIFOT = Delivery in full on time GROWTH EFFICIENCY After a weak first half, activity picked up and finished the year on strong note. Rising commodity prices had an CAPITAL EFFICIENCY increasingly positive impact on sentiment in the mining The equity ratio increased to 35% and the financial industry in 2016, but has yet to translate into higher gearing (NIBD/EBITDA) declined to 1.6, both comfortably capital investments. The cement industry is showing early within the targeted capital structure. Improved net working signs of recovery. Order intake increased 2% organically in capital and positive operating cash flow led to a reduction 2016, while revenue declined 5%. The Customer Services in net interest-bearing debt of DKK 1.1bn. and Product Companies divisions have been fairly resilient, though not immune to market headwinds, as both mining and cement companies have been holding back on discretionary spend and postponing investments in inventory and refurbishments. GUIDANCE PROFIT EFFICIENCY The EBITA margin was 7.1% in 2016 (2015: 8.0%), negatively impacted by lower revenue and under-absorption Guidance1) Realised Guidance of costs. As a consequence, corrective actions were DKK 2016 2016 2017 announced in August 2016 and the full year EBITA margin Revenue 17-18bn (17-20bn) 18.2bn 17-19bn2) guidance was narrowed to 7-8% from originally 7-9% to EBITA margin 7-8% (7-9%) 7.1% 7-9% account for one-off costs associated with the corrective ROCE 8-9% (8-10%) 8.5% 8-10% actions. Adjusted for one-off costs, the EBITA margin was 8.0% in 2016. 1) Updated in August 2016 (Announced in February 2016) 2) at prevailing currency rates FLSMIDTH ANNUAL REPORT 2016 / 4 MAIN CONCLUSIONS / BACK TO CONTENTS MAIN CONCLUSIONS ROCE REVENUE EBITA (DKKm) (DKKm) 8.5% 18,192 1,289 Down from 10.3% Down from 19,682 Down from 1,582 EBITA MARGIN CFFO ORDER INTAKE (DKKm) (DKKm) 7.1% 1,447 18,303 Down from 8.0% Up from 538 Down from 18,490 ORDER BACKLOG NET INTEREST-BEARING DEBT NET WORKING CAPITAL (DKKm) (DKKm) (DKKm) 13,887 2,525 2,099 Down from 14,858 Down from 3,674 Down from 2,583 FREE CASH FLOW FINANCIAL GEARING SERVICE ORDER INTAKE (DKKm) (NIBD/EBITDA) (DKKm) 1,253 1.6 10,029 Down from 1,288 Down from 2.0 Up from 9,660 FLSMIDTH ANNUAL REPORT 2016 / 5 MAIN CONCLUSIONS / BACK TO CONTENTS FINANCIAL RESULTS 2016 Revenue DKKm 18,192 EBITA margin 7.1% Order intake DKKm 18,303 FLSmidth Customer Product Minerals Cement Services Companies Revenue DKKm Revenue DKKm Revenue DKKm Revenue DKKm 6,555 5,015 3,185 4,286 EBITA margin EBITA margin EBITA margin EBITA margin 12.5% 11.2% -4.3% 0.6% Order intake DKKm Order intake DKKm Order intake DKKm Order intake DKKm 6,599 5,326 2,679 4,576 REVENUE SPLIT BETWEEN REVENUE SPLIT BETWEEN CEMENT AND MINERALS BUSINESS SERVICE AND CAPITAL BUSINESS Cement Minerals Capital Service business business business business 45% 55% 44% 56% EITA EITA 4.8% 8.7% FLSMIDTH ANNUAL REPORT 2016 / 6 FLSMIDTH AT A GLANCE / BACK TO CONTENTS FLSMIDTH AT A GLANCE LONG-TERM INVESTING FINANCIAL TARGETS IN FLSMIDTH Group long-term financial targets FLSmidth & Co.
Load more

Recommended publications
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • The Confusions in Nordic ESG Ratings
    Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters.
    [Show full text]
  • Honours Programme, Industrial Track Msc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering
    Honours Programme, Industrial Track MSc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering In September 2009 DTU established honours programmes within the context of the regular MSc programmes (see:www.dtu.dk/ english). The programmes are open to highly qualified internation- al and Danish students. You can choose to focus your Honours Programme in Chemical and Biochemical Engineering on industrial research and development by following a special Industrial Track. Industrial Track The superb industrial contacts and the high international standing amongst the faculty of the Department have made it possible to form an industrial track within the Honours Programme. The philosophy is to enable the very best and most motivated stu- dents to gain from high-level, world-class industrial contacts in major Danish enterprises with operations all over the world. In this way we work to open new and exciting career prospects for the students within industrial research, innovation, process design, operation and management. The programme is coordinated with leading international Danish companies. Presently FLSmidth, Lundbeck, Novozymes, Haldor- Topsøe, and Hempel support the programme. Admission to Indus- trial Track is subject to acceptance by a partner company. 2 DTU Special features The Technical University of Denmark (DTU) is Scandinavia’s leading The honours programme, Industrial Track has some special features technical university and one of the top technical universities in Europe. over and above the normal MSc programme. These are: It has outstanding facilities for education and research in a large, open campus just north of Copenhagen. Masters courses are taught in Eng- Mentoring lish, in an innovative and open-minded learning environment.
    [Show full text]
  • Ifu Project Portfolio 2018 2 | Ifu Project Portfolio 2018
    IFU PROJECT PORTFOLIO 2018 2 | IFU PROJECT PORTFOLIO 2018 PROJECT Portfolio INDEPENDENT AUDitors’ report ON IFU PROJECT Portfolio 2018 Up to the end of 2018, IFU and IFU managed funds had co-financed To the Executive Board of IFU standards, applicable requirements in Danish law and other regulations. a total of 1,286 projects in 101 countries. Of these, 203 are ongoing As agreed, we have examined the IFU Project Portfolio 2018. The IFU We complied with independence requirements and other ethical stand- investments, while IFU has exited 1,083 projects. The distribution of Project Portfolio 2018 has been listed and presented in accordance with ards under FSR - Danish Auditors’ Code of Ethics for Professional all projects by region is illustrated in the figure below. the methodology and definitions described in “Note to IFU’s project Accountants, which rely on general principles regarding integrity, ob- portfolio – definitions (only in English)”. jectivity, professional competence and due care, confidentiality and professional conduct. TotAL NUMBER OF projects DistriButeD BY REGION We are to conclude on IFU Project Portfolio 2018 to ascertain whether the data and information are correctly reflected in accordance with the As part of our examinations, we performed the below procedures: methodology and definitions reflected in “Note to IFU project portfolio • A sample check of whether IFU’s recordings of the individual share Africa 278 –definitions”. The IFU Project Portfolio 2018 means IFU’s involvement capital investments/project loans, total disbursed and expected total Asia 422 in active and finalised projects, as presented by the Executive Board and investment are reconciled in accordance with the contractual frame- Europe 445 in accordance with the principles and definitions reflected in “Note to work and information provided.
    [Show full text]
  • TO the SHAREHOLDERS of H. LUNDBECK A/S NOTICE of ANNUAL GENERAL MEETING Notice Is Hereby Given of the Annual General Meeting Of
    TO THE SHAREHOLDERS OF H. LUNDBECK A/S NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the Annual General Meeting of H. Lundbeck A/S to be held on: Thursday, 21 March 2013 at 10:00 AM The Annual General Meeting will be held at the Company’s address: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as fol- lows: 1. Report of the Board of Directors on the Company's activities during the past year. 2. Presentation and adoption of the annual report. 3. Approval of remuneration for the Board of Directors for the current financial year. 4. Resolution on the appropriation of profit or loss as recorded in the adopted annual report. 5. Election of members to the Board of Directors. 6. Election of one or two state-authorised public accountants. 7. Any proposal by shareholders or the Board of Directors. 8. Any other business. Complete proposals Re agenda item 1: The Board of Directors recommends that the report should be adopted. Re agenda item 2: It is proposed that the annual report should be adopted. Re agenda item 3: It is proposed that the remuneration for the Board of Directors for the current financial year should be the same as in 2012: - Ordinary members will receive a basic remuneration of DKK 300,000 - The chairman will receive three times the basic remuneration - The deputy chairman will receive two times the basic remuneration - Ordinary members of the Audit Committee, the Remuneration Committee and the Scien- tific Committee will receive DKK 200,000 in addition to the basic remuneration - The Committee chairmen will receive DKK 300,000 in addition to the basic remuneration Re agenda item 4: It is proposed that a dividend of 35% of the net profit for the year, corresponding to DKK 2.00 per share, or a total dividend of DKK 392 million, should be distributed for the financial year 2012.
    [Show full text]
  • Financial Results & Business Update Q1 2021
    Financial results & business update Q1 2021 11 MAY, 2021 COMPANY DISCLAIMER This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses. The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Lundbeck Continues to Deliver Solid Growth for Strategic Brands and the Financial Guidance Range Has Been Updated
    Corporate Release Valby, Denmark, August 18, 2021 Financial report for the period January 1 to June 30, 2021 Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated HIGHLIGHTS Revenue reached DKK 8,233 million in the first half of 2021, a decline of 4% in local currencies because of generic erosion on Northera®. EBIT grew 58% compared to the same period in 2020 and reached DKK 1,478 million. EBIT margin reached 18.0%. EPS grew by 63% for the period, reaching DKK 5.03. In aggregate, strategic brands grew 13% in local currencies reaching DKK 4,408 million in the first half of the year or 54% of total revenue. In the second quarter of 2021, all strategic brands have resumed double-digit growth in local currencies. Based on trends in Trintellix and Rexulti, there is a gradual uptick in new patient starts supporting growth momentum. The newest product in the portfolio, Vyepti®, continues its strong momentum since launch in April 2020 and reached DKK 101 million in the second quarter of 2021 compared to DKK 14 million for the same period last year. Regulatory review is ongoing in 14 markets. Strategic brand performance: ➢ Revenue of Abilify Maintena®: DKK 1,197 million (up 5% in local currencies, +2% reported) ➢ Revenue of Brintellix®/Trintellix®: DKK 1,656 million (up 12% in local currencies, +5% reported) ➢ Revenue of Rexulti®/Rxulti®: DKK 1,378 million (up 9% in local currencies, -1% reported) ➢ Revenue of Vyepti®: DKK 177 million (up 1,245% in local currencies, +1,164% reported) Market performance: ➢ Revenue in North America: DKK 4,052 million (down 10% in local currencies, -17% reported) ➢ Revenue in International Markets: DKK 2,197 million (up 6% in local currencies, -1% reported) ➢ Revenue in Europe: DKK 1,729 million (up 3% in local currencies, +2% reported) In connection with the financial report, Lundbeck’s President and CEO Deborah Dunsire said: “I am proud of our performance and our solid financial results as the strategic brand growth accelerates post pandemic.
    [Show full text]
  • PP Hemmingsen
    Lundbeck Foundation EU conference: Giving more to research in Europe Presentation by Steen Hemmingsen, Managing Director, The Lundbeck Foundation - The Danish research funding system - The Danish foundation sector a. Charitable b. Industrial c. Dual purpose (Commercial Foundation Act) - The Lundbeck Foundation - Trust Deed and Governance - Grant policies - Centres of Excellence - Interaction between Foundation controlled pharma industry, university research and biotech cluster March 2006 Lundbeck Foundation TheThe DanishDanish ResearchResearch FundingFunding System*System* Private sector Euro 3,44 bn. 70% 1,78% of GNP Public sector Euro 1,49 bn. 30% 0,79% - - • Council for independent research Euro 124 m. • Council for strategic research Euro 47 m. • National research foundation Euro 27 m. • Technology foundation Euro 26 m. Private foundations**) Euro 134 m. (The Lundbeck Foundation contributes Euro 30 m.) *) Source: The Danish Centre for Studies in Research and Research Policy, some figures relate to 2003. **) Estimate 2005, included in public sector statistics. Lundbeck Foundation THETHE LUNDBECKLUNDBECK FOUNDATIONFOUNDATION • Established in 1954 by Mrs. Grete Lundbeck (no descendants) • Owns 70% of the listed pharmaceutical company H. Lundbeck A/S • An industrial foundation regulated under The Commercial Foundations Act. • Several large Danish companies are controlled by industrial foundations • The Lundbeck Foundation operates independently of its industrial subsidiary/founder family - no company executives on the Board/management - no grants given to company • The Lundbeck Foundation provides grants to research of Euro 30 m. H. Lundbeck A/S has a R&D budget of Euro 250 m. • The Lundbeck Foundation’s asset base is Euro 4 bn. – 65% hereof in donor stock Lundbeck Foundation SeveralSeveral foundationfoundation--ownedowned companiescompanies amongamong thethe largestlargest DanishDanish firmsfirms • A.
    [Show full text]
  • Jens Howitz (Pdf)
    Ledelsesevaluering og mangfoldighed Jens M. Howitz Managing Director Russell Reynolds Associates Januar 2014 Bestyrelsesprofil under forandring 1999 2013 Hvid, mand, midaldrende Mangfoldighed: Køn, alder, erfaring Homogen profil “Old Boys Network” Overvejende international/global Relationer og kontakter Udvælgelsesproces Dansk Kompetencedrevet Specifik baggrund og indsigt: Tidligere CEO / Generalist • Finans, SCM, Branding, CSR etc. Advokat •Emerging markeder •Brancheforståelse •Uafhængighed FTSE 100 CAC40 DAX AEX OBX OMX C20 ‘09 ‘12 ‘09 ‘12 ‘09 ’12 ‘09 ‘12 ‘09 ‘13 ’09 ’13 Female 11% 21% 8% 22% 5% 10% 14% 20% 39% 38% 10% 16% NEDs ‘Foreign’ 37% 41% 28% 31% 18% 26% 48% 53% 27% 39% 24% 35% NEDs Average Age 57 60 60 61 61 62 62 61 54 52 58 57 2 Virksomheder Novo Nordisk Lundbeck A.P.Møller – Maersk GN Store Nord Danske Bank Jyske Bank Carlsberg Topdanmark Coloplast FLSmidth & Co. Novozymes DONG Energy TDC Danish Crown Pandora Coop Danmark Vestas Wind Systems DLG Tryg Danfoss DSV Grundfos William Demant Holding LEGO Chr. Hansen Holding 3 Bestyrelsesmedlemmer 2013 vs. 2003 Anciennitet i top 25 virksomheder i DK 2013 Anciennitet i top 25 virksomheder i DK 2003 100 45 90 40 80 35 70 30 60 25 Antal Medlemmer Antal Medlemmer 50 Mænd Mænd 20 40 Kvinder Kvinder 15 30 20 10 10 5 0 0 0-3 år 3-6 år 6-9 år 9-12 år 12+ 0-3 år 3-6 år 6-9 år 9-12 år 12+ 4 Bestyrelsesmedlemmers nationalitet, top 25 2013 2003 3% 13% 6% 13% Dansk Dansk Nordisk Nordisk Andet Andet 74% 91% 5 Bestyrelsessammensætning, top 25 2013 2003 Køn: 83,9 % mænd
    [Show full text]
  • Lamotrigine Orally Disintegrating Tablet
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3001-14 Program Step Therapy - Anticonvulsants Medication/Therapeutic Anticonvulsants – Class Depakote®, Depakote ER®, Felbatol, Keppra® , Keppra® XR®, Lamictal®, Lamictal XR®, Lamictal ODT®, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Lyrica, Mysoline, Neurontin®, Onfi, Oxtellar™ XR*, Qudexy XR* (brand and authorized generic), Sabril, Spritam*, Topamax®, Trileptal®, Trokendi® XR*, Zonegran® P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018, 9/2019, 10/2020, 6/2021 Effective Date 9/1/2021; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Lyrica, Mysoline, Neurontin, Onfi, Sabril, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*.
    [Show full text]
  • Flsmidth Sustainability Report 2020 Are Produced with Reference to Specific Mandatory and Selected Voluntary Standards and Frameworks
    WE DISCOVER POTENTIAL SUSTAINABILITY REPORT 2020 Enabling zero emissions in key industries CONTENTS Enabling zero emissions in key industries Improving our operational sustainability Letter to our stakeholders 3 Pandemic impact and actions 29 TOWARDS ZERO FLSmidth at a glance 5 Governance and sustainability risk management 30 FLSmidth in the world 6 Stakeholder engagement 33 EMISSIONS Strategy 7 Cases 35 Towards zero emissions in mining and cement 8 Safety 36 IN MINING AND Our 2030 goals and targets support the SDGs 9 Compliance 38 CEMENT Our impact across the value chain 11 People 41 Science-based targets and how they will lead us Environment 44 towards zero 12 Human rights 46 Supply chain 48 Delivering solutions to our customers Minerals and cement are all around us 14 Summarised reporting and notes Global development drivers 15 Performance summary 51 Sustainable solutions to our mining customers 16 Accounting practices 53 Sustainable solutions across the cement flowsheet 17 SDG targets 56 Solutions for a green transition 18 With MissionZero, we enable our customers New and descoped indicators 58 Cement – enabling low-impact cement production 19 in cement and mining to move towards zero Standards and disclosures 59 The road to zero emissions in cement 20 emissions by 2030. As a leader in the cement Independent auditor's limited assurance report 60 The cement process 21 Global Reporting Initiative (GRI) 61 and mining industries, we see a significant Roadmap towards zero CO emissions in cement 22 2 business opportunity in bringing these industries Cases 23 towards a sustainable future. READ MORE ON PAGE 9 Mining – the need to extract commodities responsibly 24 The road to low-impact mining 25 The mining process 26 Towards a zero water mine 27 ABOUT THIS REPORT The 2020 Sustainability Report describes the non-financial performance of FLSmidth & Co.
    [Show full text]